Azenta stock upgraded to Outperform by Raymond James on margin improvement

Raymond James upgraded Azenta (NASDAQ:AZTA) to Outperform with a $35 price target, citing the stock's undervaluation after a 50% decline, an oversold condition, and a strong balance sheet. This upgrade follows Azenta's mixed fiscal Q3 2025 results, which showed an EPS beat of $0.19 against expectations of $0.13, but a revenue miss at $144 million versus $149.51 million anticipated. The firm believes the stock has potentially bottomed, driven by effective cost-saving initiatives and future catalysts, despite the recent revenue shortfall.

Analysis

Raymond James has upgraded Azenta, Inc. (AZTA) to Outperform from Market Perform, establishing a $35.00 price target, which suggests notable upside from its current price of $26.90. This upgrade is contextualized by the stock's significant decline of over 50% in the past six months, a move that has pushed it into what is described as undervalued and oversold territory. The analyst action follows Azenta's mixed fiscal third-quarter 2025 results, which featured a substantial earnings beat with an EPS of $0.19 versus a $0.13 estimate, but also a revenue shortfall of $144 million against a $149.51 million expectation. Raymond James posits that the stock has likely found a bottom, supported by a strong balance sheet holding more cash than debt and evidence that cost-saving initiatives under a refreshed management team are proving effective. The firm's bullish thesis hinges on the belief that a business of Azenta's profile should command a double-digit EBITDA multiple, with identified catalysts such as improving NIH funding sentiment and C&I timing dynamics expected to drive future performance.

Key Decisions for Investors

• Given the Raymond James upgrade, a $35 price target, and the stock's oversold condition following a 50% decline, investors may view the current valuation as an attractive entry point.
• Investors should weigh the positive 46.15% EPS surprise against the recent top-line miss, monitoring future earnings for signs of a return to revenue growth to validate the operational turnaround thesis.
• The company's strong balance sheet, characterized by more cash than debt, provides a financial cushion that could mitigate downside risk while management's efficiency initiatives mature.
• Key catalysts to monitor include any shifts in NIH funding sentiment and developments in the company's C&I business, as these were cited as specific drivers for future performance.